Pharmacodynamic differences between canagliflozin and dapagliflozin: Results of a randomized, double-blind, crossover study

Diabetes, Obesity and Metabolism

Volumn 17, Issue 2, 2015, Pages 188-197

  Sha, S ^a   Polidori, D ^b   Farrell, K ^a   Ghosh, A ^a   Natarajan, J ^a   Vaccaro, N ^b   Pinheiro, J ^a   Rothenberg, P ^a   Plum Morschel L ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Profil   (Germany)

Author keywords

Canagliflozin; Dapagliflozin; Pharmacodynamics; Phase I II study; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

BILIRUBIN; CANAGLIFLOZIN; CREATINE KINASE; DAPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; THIOPHENE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EC50; FATIGUE; FEMALE; FLATULENCE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; IC50; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; OROPHARYNX PAIN; PHARMACODYNAMICS; PHARYNGITIS; PLASMA CONCENTRATION-TIME CURVE; POLLAKISURIA; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; TREATMENT DURATION; UPPER ABDOMINAL PAIN; URINARY EXCRETION; AGED; BODY WEIGHT; DRUG ADMINISTRATION; DRUG EFFECTS; KIDNEY; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; THIOPHENES;

EID: 84921433098     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12418     Document Type: Article

References (32)

1. Davis CS, Fleming JW, Warrington LE. Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus. J Am Assoc Nurse Pract 2014; 26: 356-363.
2. Kim GW, Chung SH. Clinical implication of SGLT2 inhibitors in type 2 diabetes. Arch Pharm Res 2014; 37: 957-966.
3. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: E867-E871.
4. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672.
5. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545.
6. Defronzo RA, Hompesch M, Kasichayanula S et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013; 36: 3169-3176.
7. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014; 53: 17-27.
8. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
9. Polidori D, Sha S, Mudaliar S et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013; 36: 2154-2161.
10. FORXIGA™. Summary of Product Characteristics. Forxiga 5 mg and 10 mg Film-coated Tablets. Middlesex: Bristol-Myers Squibb/AstraZeneca EEIG, 2014.
11. Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555.
12. Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-610.
13. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
14. Devineni D, Vaccaro N, Polidori D, Stieltjes H, Wajs E. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Int J Clin Pharmacol Ther 2014; DOI:10.5414/CP202218.
15. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 34-42.
16. Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006; 21: 2166-2171.
17. Stein P, Berg JK, Morrow L et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism 2014; 63: 1296-1303.
18. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84.
19. Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
20. Forst T, Guthrie R, Goldenberg R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477.
21. Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592.
22. Stenlöf K, Cefalu WT, Kim K-A et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
23. Stenlöf K, Cefalu WT, Kim KA et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175.
24. Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
25. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
26. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016-1027.
27. Leiter LA, Yoon K-H, Arias P et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care 2014; DOI:10.2337/dc13-2762.
28. Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 2014; 9: e105638.
29. Sha S, Polidori D, Heise T et al. Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 1087-1095.
30. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862.
31. ® (Canagliflozin) Tablets, for Oral Use [Package Insert]. Titusville: Janssen Pharmaceuticals, 2014.
32. FARXIGA™ (Dapagliflozin) Tablets, for Oral Use [Package Insert]. Princeton: Bristol-Myers Squibb Company, 2014.